| Literature DB >> 30044476 |
Mario Bargetzi1, Reto Baumann2, Sergio Cogliatti3, Pierre-Yves Dietrich4, Michel Duchosal5, Jeroen Goede6, Felicitas Hitz1, Carolin Konermann2, Andreas Lohri7, Ulrich Mey8, Urban Novak9, Alexandros Papachristofilou10, Frank Stenner11, Christian Taverna12, Thilo Zander13, Christoph Renner14.
Abstract
Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life. In addition to established regimens such as radiotherapy and immunochemotherapy, new treatment options are on the horizon. Furthermore, even the use of established chemotherapy agents has evolved, with new combinations moving to the forefront of the current treatment strategy. Nevertheless, there remains an unmet need for patients who have early relapses, those who are not responsive to anti-CD20 treatment regimens and for those in whom minimal residual disease persists even after immunochemotherapy. This review provides a summary of current developments in the diagnosis, treatment and management of follicular lymphoma, focusing on the clinical issues from a Swiss perspective.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30044476 DOI: 10.4414/smw.2018.14635
Source DB: PubMed Journal: Swiss Med Wkly ISSN: 0036-7672 Impact factor: 2.193